Zdrowie i gospodarka · 17/09/2014

FDA Publishes Final Guidance on Refuse-to-Receive Standards for Abbreviated New Drug Applications

The US Food and Drug Administration (FDA) has released a final guidance document to help pharmaceutical companies prepare their submissions for abbreviated new drug applications (ANDAs), outlining the types of serious deficiencies that may lead to the FDA refusing to receive the application